Trials / Unknown
UnknownNCT00559117
A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer
A Phase I, Open-Label, Dose Ranging Study to Assess the Safety and Distribution of Single or Multiple Doses of VB-111 in Patients With Advanced Metastatic Cancer
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Aim of the study is to evaluate the safety and find the maximal tolerated dose of VB-111 in Patients with Advanced Metastatic Cancer
Detailed description
Nine Cohorts of dose escalating VB-111 were completed with a total of 56 subjects enrolled.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VB-111 | A single intravenously infusion of diluted VB-111 should be administered 1 ml/minute |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2015-06-01
- Completion
- 2015-06-01
- First posted
- 2007-11-16
- Last updated
- 2015-03-27
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00559117. Inclusion in this directory is not an endorsement.